Use of progression-free survival (PFS) to predict overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

被引：0
|
作者：
Halabi, S.
Rini, B. I.
Stadler, W. M.
Small, E. J.
机构：
[1] Duke Univ, Med Ctr, Durham, NC USA
[2] Cleveland Clin, Cleveland, OH 44106 USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4525
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Overall and progression-free survival according to MSKCC scores in 1st line sunitinib treatment of metastatic renal cell carcinoma (mRCC)
    Finek, J.
    Poprach, A.
    Melichar, B.
    Kopecky, J.
    Zemanova, M.
    Buchler, T.
    Kopeckova, K.
    Mlcoch, T.
    Dolezal, T.
    Fiala, O.
    ANNALS OF ONCOLOGY, 2019, 30 : 387 - 387
  • [42] RELATIONSHIP BETWEEN OVERALL RESPONSE RATE (ORR), PROGRESSION-FREE SURVIVAL (PFS), AND OVERALL SURVIVAL (OS) IN CLINICAL TRIALS OF PATIENTS WITH MANTLE CELL LYMPHOMA (MCL)
    Jen, M. H.
    Sonksen, M.
    Hess, L.
    Bian, F.
    VALUE IN HEALTH, 2023, 26 (06) : S44 - S44
  • [43] ASSOCIATION BETWEEN PROGRESSION-FREE SURVIVAL (PFS) AND OVERALL SURVIVAL (OS) IN PATIENTS WITH RELAPSED/REFRACTORY (RR) MULTIPLE MYELOMA (MM)
    Mastikhina, L.
    Cope, S.
    Marshall, T.
    Maciel, D.
    Mojebi, A.
    Karampampa, K.
    Dhanda, D.
    VALUE IN HEALTH, 2023, 26 (12) : S30 - S31
  • [44] Influence of clinical trial participation with regard to overall survival (OS) and progression-free survival (PFS) for patients with advanced breast cancer
    Kiechle, M.
    Simstich, N. S.
    Schwarz-Boeger, U. R.
    Paepke, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Quality of life (QOL) predicts for progression-free survival (PFS) in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib compared to interferon-alpha (IFN-α)
    Cella, D.
    Li, J. Z.
    Cappelleri, J. C.
    Bushmakin, A.
    Charbonneau, C.
    Kim, S. T.
    Chen, I.
    Michaelson, M. D.
    Motzer, R. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] PROGRESSION-FREE SURVIVAL (PFS) IS CORRELATED WITH OVERALL SURVIVAL (OS) IN CLINICAL STUDIES OF TARGETED THERAPIES PLUS CHEMOTHERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC)
    Sidhu, Roger
    Rong, Alan
    Dahlberg, Steve
    ANNALS OF ONCOLOGY, 2011, 22 : v120 - v120
  • [47] Nomograms for overall survival (OS) and progression-free survival (PFS) in metastatic colorectal cancer (mCRC): Construction from 19,678 ARCAD patients.
    Sjoquist, Katrin Marie
    Renfro, Lindsay A.
    Simes, John
    Tebbutt, Niall C.
    Clarke, Stephen John
    Meyers, Jeffrey P.
    Gonsalves, Wilson I.
    Adams, Richard
    Seymour, Matthew T.
    Saltz, Leonard
    Schmoll, Hans
    Sargent, Daniel J.
    De Gramont, Aimery
    Zalcberg, John Raymond
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [48] Evaluation of overall survival (OS), progression-free survival (PFS), or time to progression (TTP) in systematic review of randomized clinical trials (RCT) in patients with metastatic breast cancer (MBC)
    Mukonje, Terence
    Santana-Davila, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Use of bisphosphonates (Bis) combined with sunitinib (Su) to improve the response rate (RR), progression-free survival (PFS), and overall survival (OS) of patients (pts) with bone metastases (mets) from renal cell carcinoma (RCC)
    Peer, Avivit
    Ish-Shalom, Maya
    Hammers, Hans J.
    Eisenberger, Mario A.
    Sinibaldi, Victoria J.
    Pili, Roberto
    Maimon, Natalie
    Gottfried, Maya
    Hayat, Henry
    Kovel, Svetlana
    Sella, Avishay
    Neumann, Avivit
    Boursi, Ben
    Berger, Raanan
    Carducci, Michael Anthony
    Keizman, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Validity and efficiency of progression-free survival (PFS)-2 as a surrogate endpoint for overall survival (OS) in advanced cancer.
    Woodford, Rachel
    Zhou, Deborah
    Kok, Peey-Sei
    Lord, Sally
    Friedlander, Michael
    Marschner, Ian
    Simes, John
    Lee, Chee Khoon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345